Literature DB >> 7053312

Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection.

G R Granneman, L T Sennello, R C Sonders, B Wynne, E W Thomas.   

Abstract

We evaluated cefsulodin kinetics in normal subjects after 250-, 500-, and 1,000-mg, intramuscular injections and 500-, 1,000-, and 2,000-mg 30-min intravenous infusions. Twelve plasma and four urine samples were collected in the first 12 and 24 hr. Plasma samples were analyzed by a new, highly precise high-performance liquid chromatographic procedure developed in our laboratory and urine samples were analyzed microbiologically, using Pseudomonas aeruginosa as the test organism. Mean calculated peak plasma levels from the 250-, 500-, and 1,000-mg intramuscular doses were 5.46, 11.81, and 19.40 microgram/ml. After 500-, 1,000-, and 2,000-mg intravenous infusions peak levels were 32.7, 65.7, and 190.1 microgram/ml. Data from the intramuscular doses were fitted to a one-compartment open kinetic model, yielding a mean elimination half-life (t1/2) of 1.9 hr. Data from the intravenous infusions were fitted to a two-compartment open model, with a mean beta-phase t1/2 of 1.6 hr. Mean 0- to 24-hr urinary recoveries after the three intramuscular doses were 50.0%, 54.5%, and 51.2% of total dose; after the three intravenous doses they were 60.4%, 52.4%, and 54.0%. Cefsulodin kinetics were shown to be consistent and orderly.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053312     DOI: 10.1038/clpt.1982.15

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.

Authors:  A Hedman; G Alván; B Strandvik; A Arvidsson
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.

Authors:  F Sörgel; U Stephan; H G Wiesemann; B Gottschalk; C Stehr; M Rey; H B Böwing; H C Dominick; M Geldmacher von Mallinckrodt
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  Pharmacokinetics of ceftazidime in male and female volunteers.

Authors:  D K Sommers; L Walters; M Van Wyk; S M Harding; A M Paton; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 4.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

6.  Cefsulodin sodium therapy in cystic fibrosis patients.

Authors:  I Cabezudo; R L Thompson; R F Selden; S H Guenthner; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

7.  Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; T S Yamashita; I Ackers; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  Cefsulodin pharmacokinetics in patients with various degrees of renal function.

Authors:  G R Matzke; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.